Part I: Description of consignment

I.1. Consignor
Name
Address
Country ISO Code

I.2. IMSOC reference

I.2.a. Local reference

I.3. Central Competent Authority

I.4. Local Competent Authority

I.5. Consignee
Name
Address
Country ISO Code

I.6. Operator conducting assembly operations independently of an establishment
Name
Address
Approval Number
Country ISO Code

I.7. Country of origin ISO Code

I.8. Region of origin Code

I.9. Country of destination ISO Code

I.10. Region of destination Code

I.11. Place of dispatch
Name
Address
Approval Number
Country ISO Code

I.12. Place of destination
Name
Address
Approval Number
Country ISO Code

I.13. Place of loading
Name
Address
Approval Number
Country ISO Code

I.14. Date and time of departure

I.15. Means of Transport

Mode	International transport document	Identification

I.16. Transporter
Name
Address
Activity ID
Country ISO Code

I.17. Accompanying documents
Accompanying document reference
Date of issue
Country
Place of issue

I.18. Transport conditions
Ambient ☐ Chilled ☐ Frozen ☐

I.19. Container No / Seal No

I.20. Certified as
Germinal products ☐

I.21. For transit through a third country ☐
Third country ISO Code
Exit point BCP code
Entry point BCP code

I.22. For transit through Member State(s) ☐
Member State ISO Code

I.23. For export ☐
Third country ISO Code
Exit point BCP code

I.24. Estimated journey time

I.25. Journey Log

I.26. Total number of packages	I.27. Total quantity	I.28. Total gross weight

I.30. Description of consignment

1. 05 PRODUCTS OF ANIMAL ORIGIN, NOT ELSEWHERE SPECIFIED OR INCLUDED

0511 Animal products not elsewhere specified or included; dead animals of Chapter | 1 | or 3, unfit for human consumption

051199 Other

05119985 Other

#1.	Commodity	Identification Number	Quantity	Nature of commodity	Identification Mark
Species		Package count	Date of collection / production	Plant / Establishment / Centre	Type

Part II: Certification

II. Health information

I, the undersigned official veterinarian, hereby certify that:

(1) ☐ [II.1. The in vivo derived embryos of bovine animals described in Part I have been collected, processed and stored, and dispatched by the embryo collection team(2) which

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Delegated Regulation (EU) 2020/686.]

(1) ☐ [II.1. The oocytes(1)/ in vitro produced embryos(1)/ micromanipulated embryos(1) of bovine animals described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team(2) which

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]

II.2. The oocytes(1)/ embryos(1) described in Part I are intended for artificial reproduction and were obtained from donor animals which

II.2.1. have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;

II.2.2. come from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof

II.2.2.1. free from infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis), and they have never been kept previously in any establishment of a lower health status;

II.2.2.2. free from infection with Brucella abortus, B. melitensis and B. suis and they have never been kept previously in any establishment of a lower health status;

(1) ○ either [II.2.2.3. free from enzootic bovine leukosis and they have never been kept previously in any establishment of a lower health status;]

(1) ○ or [II.2.2.3. not free from enzootic bovine leukosis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of enzootic bovine leukosis during a period of at least the preceding 3 years;]

(1) ○ either [II.2.2.4. free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and they have never been kept previously in any establishment of a lower health status;]

(1) ○ or [II.2.2.4. not free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of infectious bovine rhinotracheitis/infectious pustular vulvovaginitis during a period of at least the preceding 12 months;]

II.2.2.5. in which surra (Trypanosoma evansi) has not been reported during the 30 day period prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and

(1) ○ either [surra has not been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]

(1) ○ or [surra has been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak the establishments have remained under movement restrictions until

- the infected animals have been removed from

Part II: Certification

II. Health information

					the establishment, and
				-	the remaining animals on the establishment have been subjected to a test for surra (Trypanosoma evansi) with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the infected animals have been removed from the establishment;]
	II.2.3.	were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the day of collection(1)/ production(1) of the oocytes(1)/ embryos(1);			
	II.2.4.	are individually identified as provided for in Article 38 of Commission Delegated Regulation (EU) 2019/2035;			
	II.2.5.	for a period of at least 30 days prior to the date of first collection(1)/ production(1) of the oocytes(1)/ embryos(1) and during the collection period			
			II.2.5.1.	were kept on establishments not situated in a restricted zone established due to the occurrence of foot-and-mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia or lumpy skin disease or of an emerging disease relevant for bovine animals;	
			II.2.5.2.	were kept on a single establishment where infection with Brucella abortus, B. melitensis and B. suis, infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis), rabies, anthrax, surra (Trypanosoma evansi), enzootic bovine leukosis, infectious bovine rhinotracheitis/infectious pustular vulvovaginitis, bovine viral diarrhoea, infection with epizootic haemorrhagic disease virus and infection with bluetongue virus (serotypes 1-24) have not been reported;	
			II.2.5.3.	were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.2.5.1. or from establishments which do not meet the conditions referred to in point II.2.5.2.;	
			II.2.5.4.	were not used for natural breeding;	
	II.2.6.	comply with the following conditions as regards foot-and-mouth disease			
			II.2.6.1.	they come from establishments	
					- situated in an area where foot-and-mouth disease has not been reported within a 10-km radius centred on the establishment for a period of at least 30 days immediately prior to the date of collection of the oocytes(1)/ embryos(1);
					- in which foot-and-mouth disease has not been reported during a period of at least 3 months immediately prior to the date of collection of the oocytes(1)/ embryos(1);
(1)	○ either		[II.2.6.2.	they were not vaccinated against foot-and-mouth disease;]	
(1)(3)	○ or		[II.2.6.2.	they were vaccinated against foot-and-mouth disease during the period of 12 months prior to the date of collection or production of the embryos and	
				II.2.6.2.1.	have not been vaccinated against foot-and-mouth disease within the period of at least 30 days immediately prior to the date of collection of the embryos;

Part II: Certification

II. Health information

			II.2.6.2.2.	the semen used for fertilisation was collected from a male donor that complies with the conditions set out in point 1(b) or the semen complies with the conditions set out in point 2 of Chapter I of Part 5 of Annex II to Delegated Regulation (EU) 2020/686;
			II.2.6.2.3.	prior to freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual(4);
			II.2.6.2.4.	the embryos were stored deep frozen for a period of at least 30 days from the date of collection, and during this period the donor animal has not shown clinical signs of foot-and-mouth disease;]
(1)(5)	☐ [II.2.7.	comply with at least one of the following conditions as regards infection with bluetongue virus (serotypes 1-24):		
(1)		☐ either	[II.2.7.1.	they have been kept for a period of at least 60 days prior to and during collection of the oocytes in a Member State or zone thereof free from infection with bluetongue virus (serotypes 1-24) where no case of infection with bluetongue virus (serotypes 1-24) has been confirmed during the last 24 months in the targeted animal population;]
(1)		☐ and/or	[II.2.7.2.	they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a Member State or zone thereof with an approved eradication programme against infection with bluetongue virus (serotypes 1-24);]
(1)		☐ and/or	[II.2.7.3.	they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a Member State or zone thereof where the competent authority of the place of origin of the consignment of oocytes(1)/in vitro produced embryos(1) has obtained the prior written consent of the competent authority of the Member State of destination to the conditions for establishment of that seasonally disease-free zone and to accept the consignment of oocytes(1)/in vitro produced embryos(1);]
(1)		☐ and/or	[II.2.7.4.	they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]
(1)		☐ and/or	[II.2.7.5.	they have been subjected to a serological test to detect antibodies to the bluetongue virus serogroup 1-24, with negative results, between 28 and 60 days from the date of each collection of the oocytes;]
(1)		☐ and/or	[II.2.7.6.	they have been subjected to an agent identification test for bluetongue virus (serotypes 1-24), with negative results, on blood sample taken on the day of collection of the oocytes;]]
(1)(5)		☐ [II.2.8.	comply with at least one of the following conditions as regards infection with epizootic haemorrhagic disease virus (serotypes 1-7) (EHDV 1-7):	
(1)		☐ either	[II.2.8.1.	they have been kept for a period of at least 60 days prior to and during collection of the oocytes in a Member State or zone thereof where EHDV 1-7 has not been reported for a period of at least the preceding 2 years within a radius of 150 km of the establishment;]
(1)		☐ and/or	[II.2.8.2.	they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]
(1)		☐ and/or	[II.2.8.3.	were resident in the Member State in which according to official findings the following serotypes of EHDV exist: and have been subjected with negative results in each case to the following tests carried out in an official laboratory:

Part II: Certification

II. Health information

(1) ☐ either [II.2.8.3.1. a serological test to detect antibodies to EHDV 1-7, with negative results, on blood sample taken between 28 and 60 days from the date of the collection of the oocytes;]]

(1) ☐ and/or [II.2.8.3.2. an agent identification test for EHDV 1-7, with negative results, on blood sample taken on the day of collection of the oocytes.]]]

(1)(5) ☐ [II.2.9. comply with animal health requirements laid down in Chapter III of Part 1 of Annex II to Delegated Regulation (EU) 2020/686.]

II.3. The oocytes(1)/ embryos(1) described in Part I

II.3.1. has been collected, processed and stored in accordance with animal health requirements set out in Part 2(1)/Part 3(1)/Part 4(1)/Part 5(1) and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;

II.3.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in Box I.30;

II.3.3. are transported in a container which:

II.3.3.1. was sealed and numbered prior to the dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in Box I.19;

II.3.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;

(1)(6) ☐ [II.3.3.3. has been filled in with the cryogenic agent which not have been previously used for other products.]

(1)(7) ☐ [II.3.4. are placed in straws or other packages which are securely and hermetically sealed;

II.3.5. are transported in a container where they are separated from each other by physical compartments or by being placed in secondary protective bags.]

(1)(8) ☐ [II.4. The in vivo derived embryos(1)/ in vitro produced embryos(1)/ micromanipulated embryos(1) described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a Member State or by the competent authority of a third country, territory or zone thereof listed in Annex IX to Commission Implementing Regulation (EU) 2021/404.]

(1)(9) ☐ [II.5. The following antibiotic or mixture of antibiotics(10) has been added to the collection, processing, washing or storage media:]

(2) ○ either [II.6 Germinal products (semen, ova and/or embryos, indicate as appropriate) obtained from bovine animals kept in vaccination zone I in relation to emergency protective vaccination against lumpy skin disease, in compliance with Article 13(3) of, and Annex IX, Part 3, point (3.4.1), to Commission Delegated Regulation (EU) 2023/361.]

(2) ○ or<JsUMP> [II.6 Germinal products (semen, ova and/or embryos, indicate as appropriate) obtained from bovine animals kept in vaccination zone II in relation to emergency protective vaccination against lumpy skin disease, in compliance with Article 13(3) of, and Annex IX, Part 3, point (3.4.2), to Commission Delegated Regulation (EU) 2023/361.]

Notes

This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Part II: Certification

II. Health information		

Box reference I.11:	“Place of dispatch”: Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.
Box reference I.12:	“Place of destination”: Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.
Box reference I.19:	Seal number shall be indicated.
Box reference I.26:	Total number of packages shall correspond to the number of containers.
Box reference I.30:	“Species”: Select amongst “Bos taurus”, “Bison bison" or "Bubalus bubalis” as appropriate.
	“Type”: Specify if oocytes, in vivo derived embryos, in vitro produced embryos or micromanipulated embryos.
	“Identification number”: Indicate the identification number of each donor animal.
	“Identification mark”: Indicate the mark on the straw or other packages where oocytes or embryos of the consignment are placed.
	“Date of collection/production”: Indicate the date on which oocytes or embryos of the consignment were collected or produced.
	“Approval or registration number of plant/establishment/centre”: Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos were collected or produced.
	“Quantity”: Indicate the number of straws or other packages with the same mark.
	“Test”: Indicate for BTV-test: II.2.7.5. and/or II.2.7.6., and/or for EHD-test: II.2.8.3.1. and/or II.2.8.3.2., if relevant.

Part II:

(1)	Delete if not applicable.
(2)	Only embryo collection or production teams approved by the competent authority and included in the register referred to in Article 101(1)(b) of Regulation (EU) 2016/429 and Article 7 of Delegated Regulation (EU) 2020/686.
(3)	Option available only for the consignment of in vivo derived embryos.
(4)	Manual of the International Embryo Transfer Society — A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Transfer Society, 1 111 North Dunlap Avenue, Savoy, Illinois 61 874 USA (http://www.iets.org/).
(5)	Applicable for the consignment of oocytes and in vitro produced embryos.
(6)	Applicable for frozen oocytes or embryos.
(7)	Applicable for the consignment where in one container oocytes, in vivo derived embryos, in vitro produced embryos and micromanipulated embryos of bovine animals are placed and transported.
(8)	Does not apply to oocytes.
(9)	Mandatory attestation in case antibiotics were added.
(10)	Insert the name(s) of the antibiotic(s) added and its(their) concentration.

Certifying Officer/Official veterinarian	
Name (in capital letters)	Qualification and title
Date of signature	Signature
Stamp	